OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2129-2132
Open Access | Times Cited: 33
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2129-2132
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 11
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 11
Interferons in the treatment of myeloproliferative neoplasms
Pankit Vachhani, John O. Mascarenhas, Prithviraj Bose, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 8
Pankit Vachhani, John O. Mascarenhas, Prithviraj Bose, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 8
Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment
Albert Qin
Clinical Therapeutics (2024) Vol. 46, Iss. 5, pp. 439-440
Closed Access | Times Cited: 8
Albert Qin
Clinical Therapeutics (2024) Vol. 46, Iss. 5, pp. 439-440
Closed Access | Times Cited: 8
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
S. Suo, Rong Feng Fu, Albert Qin, et al.
Journal of Hematology (2024) Vol. 13, Iss. 1-2, pp. 12-22
Open Access | Times Cited: 7
S. Suo, Rong Feng Fu, Albert Qin, et al.
Journal of Hematology (2024) Vol. 13, Iss. 1-2, pp. 12-22
Open Access | Times Cited: 7
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes
Reem S. Chamseddine, Oleksandr Savenkov, Shehroz Rana, et al.
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2520-2526
Open Access | Times Cited: 5
Reem S. Chamseddine, Oleksandr Savenkov, Shehroz Rana, et al.
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2520-2526
Open Access | Times Cited: 5
Diagnosis and Treatment of Polycythemia Vera
Douglas Tremblay, Marina Kremyanskaya, John O. Mascarenhas, et al.
JAMA (2024)
Closed Access | Times Cited: 5
Douglas Tremblay, Marina Kremyanskaya, John O. Mascarenhas, et al.
JAMA (2024)
Closed Access | Times Cited: 5
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2299-2310
Open Access | Times Cited: 4
Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2299-2310
Open Access | Times Cited: 4
Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera
Albert Qin, Daoxiang Wu, Yaning Li, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 6, pp. 1493-1502
Closed Access | Times Cited: 4
Albert Qin, Daoxiang Wu, Yaning Li, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 6, pp. 1493-1502
Closed Access | Times Cited: 4
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Abdulraheem Yacoub, Ghaith Abu‐Zeinah, Albert Qin, et al.
Annals of Hematology (2025)
Open Access
Abdulraheem Yacoub, Ghaith Abu‐Zeinah, Albert Qin, et al.
Annals of Hematology (2025)
Open Access
Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system
E. Walter, Francesca Torelli, Tiziano Barbui
Annals of Hematology (2025)
Open Access
E. Walter, Francesca Torelli, Tiziano Barbui
Annals of Hematology (2025)
Open Access
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
Marc Usart, Quentin Kimmerlin, Jan Stetka, et al.
Leukemia (2025)
Closed Access
Marc Usart, Quentin Kimmerlin, Jan Stetka, et al.
Leukemia (2025)
Closed Access
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
Yan Beauverd, Jean‐Christophe Ianotto, Kyaw Htin Thaw, et al.
Leukemia (2025)
Open Access
Yan Beauverd, Jean‐Christophe Ianotto, Kyaw Htin Thaw, et al.
Leukemia (2025)
Open Access
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
Chih‐Cheng Chen, Justin L. Chen, Alex Jia-Hong Lin, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 1947-1965
Open Access | Times Cited: 4
Chih‐Cheng Chen, Justin L. Chen, Alex Jia-Hong Lin, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 1947-1965
Open Access | Times Cited: 4
Treatment‐associated decline inJAK2V617F allele burden in polycythemia vera: What does it mean?
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1459-1461
Closed Access | Times Cited: 2
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1459-1461
Closed Access | Times Cited: 2
Polycythemia vera: past, present and future
Ami B. Patel, Lucia Masarová, Ruben A. Mesa, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-13
Closed Access | Times Cited: 2
Ami B. Patel, Lucia Masarová, Ruben A. Mesa, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-13
Closed Access | Times Cited: 2
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3573-3583
Open Access | Times Cited: 2
Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3573-3583
Open Access | Times Cited: 2
Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera
Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5416-5425
Open Access | Times Cited: 2
Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5416-5425
Open Access | Times Cited: 2
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
Silvio Ligia, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 1
Silvio Ligia, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 1
How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
Mary Frances McMullin, Claire Harrison
Blood (2024)
Open Access | Times Cited: 1
Mary Frances McMullin, Claire Harrison
Blood (2024)
Open Access | Times Cited: 1
Are we ready for disease modification in myeloproliferative neoplasms?
Claire Harrison
HemaSphere (2024) Vol. 8, Iss. 9
Open Access | Times Cited: 1
Claire Harrison
HemaSphere (2024) Vol. 8, Iss. 9
Open Access | Times Cited: 1
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b
Albert Qin, Daoxiang Wu, Jason Liao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Albert Qin, Daoxiang Wu, Jason Liao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera
Keita Kirito, Yuka Sugimoto, Akihiko Gotoh, et al.
International Journal of Hematology (2024)
Open Access | Times Cited: 1
Keita Kirito, Yuka Sugimoto, Akihiko Gotoh, et al.
International Journal of Hematology (2024)
Open Access | Times Cited: 1
The evolving landscape of polycythemia vera therapies
Juana Martínez, Shivani Handa, Alexander Skorodinsky, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 11, pp. 1439-1452
Closed Access
Juana Martínez, Shivani Handa, Alexander Skorodinsky, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 11, pp. 1439-1452
Closed Access
